# Vascular PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vascular

> The FDA approved vascular, sponsored by Humacyte, Inc. (HUMA), on December 19, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is vascular FDA approved?

Yes. The FDA approved vascular, sponsored by Humacyte, Inc. (HUMA), on December 19, 2024. SEC Form 10-K: "We received our first FDA approval of the ATEV on December 19, 2024, a full approval for Symvess (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible." [Calendar and source filings](https://sec-api.dev/pdufa/vascular)

Source: SEC Form 10-K, accession 0001818382-26-000004, https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/vascular#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | vascular |
| Codes |  |
| Sponsor | Humacyte, Inc. (HUMA) https://sec-api.dev/companies/huma/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track, priority review, rmat |

## Timeline

### Sep 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2/3.
- First seen 2025-03-31, last confirmed 2026-08-12.
- SEC Form 10-Q (accession 0001193125-26-347022): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-221755): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000119312526221755/huma-20260331.htm
- SEC Form 10-Q (accession 0001818382-25-000132): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000132/huma-20250930.htm
- SEC Form 10-Q (accession 0001818382-25-000125): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000125/huma-20250630.htm
- SEC Form 10-Q (accession 0001818382-25-000076): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000076/huma-20250331.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023 we filed a Biologics License Application ("BLA") for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm

### Sep 2023: NDA/BLA submission

- Status: completed. Date confidence: month. Stage: 2/3.
- First seen 2025-03-31, last confirmed 2026-08-12.
- SEC Form 10-Q (accession 0001193125-26-347022): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-221755): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000119312526221755/huma-20260331.htm
- SEC Form 10-Q (accession 0001818382-25-000132): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000132/huma-20250930.htm
- SEC Form 10-Q (accession 0001818382-25-000125): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000125/huma-20250630.htm
- SEC Form 10-Q (accession 0001818382-25-000076): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000076/huma-20250331.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023 we filed a Biologics License Application ("BLA") for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In September 2023, we announced positive topline results from our V005 Phase 2/3 trial in vascular trauma, and in December 2023, we filed a BLA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm

### December 12, 2023: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-03-31, last confirmed 2026-08-12.
- SEC Form 10-K (accession 0001818382-26-000004): "For example, on December 12, 2023, we submitted our BLA for the ATEV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm
- SEC Form 10-K (accession 0001818382-25-000034): "On December 12, 2023, we submitted our BLA for the ATEV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm
- SEC Form 10-Q (accession 0001193125-26-347022): "In December 2023, the Company filed a BLA with the FDA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-221755): "In December 2023, the Company filed a BLA with the FDA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000119312526221755/huma-20260331.htm
- SEC Form 10-K (accession 0001818382-26-000004): "In December 2023, the Company filed a BLA with the FDA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm
- SEC Form 10-Q (accession 0001818382-25-000132): "In December 2023, the Company filed a BLA with the FDA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000132/huma-20250930.htm
- SEC Form 10-Q (accession 0001818382-25-000125): "In December 2023, the Company filed a BLA with the FDA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000125/huma-20250630.htm
- SEC Form 10-Q (accession 0001818382-25-000076): "In December 2023, the Company filed a BLA with the FDA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000076/huma-20250331.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In December 2023, the Company filed a BLA with the FDA for urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm

### Feb 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-03-31, last confirmed 2026-03-27.
- SEC Form 10-K (accession 0001818382-26-000004): "In February 2024, the FDA accepted our BLA in the vascular trauma indication and granted priority review of that BLA." https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm
- SEC Form 10-Q (accession 0001818382-25-000132): "In February 2024, the FDA accepted the Company's Biologics License Application ("BLA") for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company drew a subsequent installment of $20.0 million." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000132/huma-20250930.htm
- SEC Form 10-Q (accession 0001818382-25-000125): "In February 2024, the FDA accepted the Company's Biologics License Application ("BLA") for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company drew a subsequent installment of $20.0 million." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000125/huma-20250630.htm
- SEC Form 10-Q (accession 0001818382-25-000076): "In February 2024, the FDA accepted the Company's Biologics License Application ("BLA") for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company drew a subsequent installment of $20.0 million." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000076/huma-20250331.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In February 2024, the FDA accepted our BLA in the vascular trauma indication and granted priority review of that BLA." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In February 2024, the FDA accepted the Company's BLA for an indication in vascular trauma, and in accordance with the Purchase Agreement, on March 11, 2024, the Company received a subsequent installment of $20.0 million." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-031780): "In February 2024, the FDA accepted our BLA in the vascular trauma indication and granted priority review of that BLA." https://www.sec.gov/Archives/edgar/data/1818382/000110465926031780/tm269106d1_ex99-2.htm

### December 19, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-28, last confirmed 2026-11-10.
- SEC Form 10-K (accession 0001818382-26-000004): "We received our first FDA approval of the ATEV on December 19, 2024, a full approval for Symvess (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm
- SEC Form 10-K (accession 0001818382-26-000004): "On December 19, 2024, the FDA granted full approval of our BLA for the vascular trauma indication, and we elected not to draw the additional $40.0 million that became available under the Purchase Agreement." https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm
- SEC Form 10-Q (accession 0001193125-26-347022): "In December 2024, the FDA approved the Company's BLA for urgent arterial repair following extremity vascular trauma when autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000119312526347022/huma-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-221755): "In December 2024, the FDA approved the Company's BLA for urgent arterial repair following extremity vascular trauma when autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000119312526221755/huma-20260331.htm
- SEC Form 10-K (accession 0001818382-26-000004): "Following the December 2024 FDA approval of Symvess in extremity vascular trauma, we commenced the United States commercial launch in that indication in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm
- SEC Form 10-K (accession 0001818382-26-000004): "In December 2024, the FDA approved Symvess as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible, but there can be no assurance that we will obtain approval outside of the United States for that indication or marketing approval for any of our product candidates." https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm
- SEC Form 10-K (accession 0001818382-26-000004): "In December 2024, the FDA approved the Company's BLA with the FDA for urgent arterial repair following extremity vascular trauma when autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838226000004/huma-20251231.htm
- SEC Form 10-Q (accession 0001818382-25-000132): "In December 2024, the FDA approved the Company's BLA for urgent arterial repair following extremity vascular trauma when autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000132/huma-20250930.htm
- SEC Form 10-Q (accession 0001818382-25-000125): "In December 2024, the FDA approved the Company's BLA for urgent arterial repair following extremity vascular trauma when autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000125/huma-20250630.htm
- SEC Form 10-Q (accession 0001818382-25-000076): "In December 2024, the FDA approved the Company's BLA for urgent arterial repair following extremity vascular trauma when autologous vein use is not feasible." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000076/huma-20250331.htm
- SEC Form 10-K (accession 0001818382-25-000034): "Following the December 2024 FDA approval of Symvess in extremity vascular trauma, we commenced the United States commercial launch in that indication in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm
- SEC Form 10-K (accession 0001818382-25-000034): "In December 2024, the FDA approved Symvess as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible, but there can be no assurance that we will obtain approval outside of the United States for that indication or marketing approval for any of our product candidates." https://www.sec.gov/Archives/edgar/data/1818382/000181838225000034/huma-20241231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vascular.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vascular PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vascular

```bibtex
@misc{secapidev_pdufa_vascular_20261116,
  title        = {Vascular PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vascular}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vascular_20261116","title":"Vascular PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vascular","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
